The newly developed 3-amino-1,2,4-triazines, targeting PDK, showed promising therapeutic potential for combatting highly aggressive KRAS-mutant pancreatic ductal adenocarcinoma. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.